BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29852147)

  • 1. Pericardial and Pleural Metastases: Clinical, Histologic, and Molecular Differences.
    Karpathiou G; Mobarki M; Stachowicz ML; Hathroubi S; Patoir A; Tiffet O; Froudarakis M; Peoc'h M
    Ann Thorac Surg; 2018 Sep; 106(3):872-879. PubMed ID: 29852147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
    Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
    Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytological features of lung adenocarcinoma with micropapillary pattern in the pleural or pericardial effusion: analysis of 5 cases.
    Ishida M; Kagotani A; Iwai M
    Int J Clin Exp Pathol; 2014; 7(8):5111-6. PubMed ID: 25197384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Alterations in Patients with Pulmonary Adenocarcinoma Presenting with Malignant Pleural Effusion at the First Diagnosis.
    Rodriguez EF; Shabihkhani M; Carter J; Maleki Z
    Acta Cytol; 2017; 61(3):214-222. PubMed ID: 28538219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant pleural and pericardial effusion in invasive breast cancer: impact of the site of the primary tumor.
    Pokieser W; Cassik P; Fischer G; Vesely M; Ulrich W; Peters-Engl C
    Breast Cancer Res Treat; 2004 Jan; 83(2):139-42. PubMed ID: 14997044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies.
    Forest F; Stachowicz ML; Casteillo F; Karpathiou G; Gouzy-Grosjean F; Guilaubey C; Cottier M; Beal J; Clemenson A; Péoc'h M
    Exp Mol Pathol; 2017 Dec; 103(3):306-310. PubMed ID: 29175303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.
    Schweiger T; Hegedüs B; Nikolowsky C; Hegedüs Z; Szirtes I; Mair R; Birner P; Döme B; Lang G; Klepetko W; Ankersmit HJ; Hoetzenecker K
    Ann Surg Oncol; 2014 Mar; 21(3):946-54. PubMed ID: 24281417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
    Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
    Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma.
    Dormieux A; Mezquita L; Cournede PH; Remon J; Tazdait M; Lacroix L; Rouleau E; Adam J; Bluthgen MV; Facchinetti F; Tselikas L; Aboubakar F; Naltet C; Lavaud P; Gazzah A; Le Pechoux C; Lassau N; Balleyguier C; Planchard D; Besse B; Caramella C
    Eur Radiol; 2020 Sep; 30(9):5021-5028. PubMed ID: 32323012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
    Thomas A; Chen Y; Steinberg SM; Luo J; Pack S; Raffeld M; Abdullaev Z; Alewine C; Rajan A; Giaccone G; Pastan I; Miettinen M; Hassan R
    Oncotarget; 2015 May; 6(13):11694-703. PubMed ID: 26028668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Oncogenic drivers in daily practice improve overall survival in patients with lung adenocarcinoma].
    Fournier C; Greillier L; Fina F; Secq V; Nanni-Metellus I; Loundou A; Garcia S; Ouafik L; Tomasini P; Barlesi F
    Rev Mal Respir; 2016 Nov; 33(9):751-756. PubMed ID: 27017063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
    Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
    PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of E-cadherin in pleural effusion cells predicts better prognosis in lung adenocarcinoma patients.
    Zhao C; Li X; Su C; Li J; Cheng N; Ren S; Chen X; Zhou C
    Int J Clin Exp Pathol; 2015; 8(3):3104-9. PubMed ID: 26045824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serous effusions in malignant lymphomas: a review.
    Das DK
    Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer.
    Kuijpers CCHJ; Hendriks LEL; Derks JL; Dingemans AC; van Lindert ASR; van den Heuvel MM; Damhuis RA; Willems SM
    Lung Cancer; 2018 Jul; 121():76-81. PubMed ID: 29858031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant pleural effusions after resection of pulmonary adenocarcinoma.
    Renshaw AA; Madge R; Sugarbaker DJ; Swanson S
    Acta Cytol; 1998; 42(5):1111-5. PubMed ID: 9755666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Frequency of adenocarcinomas in serous effusions].
    Longatto Filho A; Bisi H; Bortolan J; Lombardo V; Alves VA
    Rev Assoc Med Bras (1992); 1999; 45(4):327-36. PubMed ID: 10752240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.